Identification of an important potential confound in CSF AD studies: Aliquot volume

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 12, 2013, Pages 2311-2317

  Toombs, Jamie ^a   Paterson, Ross W ^a   Lunn, Michael P ^a   Nicholas, Jenifer M ^b   Fox, Nick C ^a   Chapman, Miles D ^a   Schott, Jonathan M ^a   Zetterberg, Henrik ^a,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Alzheimer's disease; amyloid ; Cerebrospinal fluid; Tau; Volume

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; DETERGENT; POLYSORBATE 20; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HUMAN; PRIORITY JOURNAL; STORAGE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ARTIFACTS; BIOLOGICAL MARKERS; BUFFERS; HUMANS; PEPTIDE FRAGMENTS; SPECIMEN HANDLING; TAU PROTEINS;

EID: 84889578740     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2013-0293     Document Type: Article

References (13)

1. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6: 131-44.
2. Bartlett JW, Frost C, Mattsson N, Skillback T, Blennow K, Zetterberg H, et al. Determining cut-points for Alzheimer's disease biomarkers: statistical issues, methods and challenges. Biomark Med 2012;6: 391-400.
3. Schoonenboom NS, Mulder C, Vanderstichele H, Van Elk EJ, Kok A, Van Kamp GJ, et al. Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin Chem 2005;51: 189-95.
4. Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 2007;68: 666-9.
5. Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsater H, Anckarsater R, et al. Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. Int J Alzheimers Dis 2010;2010: 986310.
6. Sjogren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelso C, et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem 2001;47: 1776-81.
7. Perret-Liaudet A, Pelpel M, Tholance Y, Dumont B, Vanderstichele H, Zorzi W, et al. Cerebrospinal fluid collection tubes: a critical issue for Alzheimer disease diagnosis. Clin Chem 2012;58: 787-9.
8. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5: 228-34.
9. Conversion and calculations Aqua-Calc. Available from: www. aqua-calc.com. Accessed 21 February, 2013.
10. Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J Neurochem 2002;81: 481-96.
11. Bibl M, Esselmann H, Otto M, Lewczuk P, Cepek L, Ruther E, et al. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides. Electrophoresis 2004;25: 2912-8.
12. Kaiser E, Schonknecht P, Thomann PA, Hunt A, Schroder J. Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1-42). Neurosci Lett 2007;417: 193-5.
13. Carrillo MC, Blennow K, Soares H, Lewczuk P, Mattsson N, Oberoi P, et al. Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: an update from the Alzheimer's Association Global Biomarkers Consortium. Alzheimers Dement 2013;9: 137-40.